A retroviral DNA vaccine vector

James M. Smith, Jose V Torres

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A versatile DNA vaccine (pdIV3) was constructed by replacing the integrase, vif, vpx, and vpr genes of a pathogenic simian immunodeficiency virus (SIV) molecular clone with a linker containing unique cloning sites. The 5′ long terminal repeat (LTR) is truncated and transcription is controlled by a cytomegalovirus (CMV) promoter. The construct expresses Gag and Env in vitro and noninfectious virus particles are produced from transfected cells. The ability of pdIV3 to promote cellular and humoral immune responses, along with the flexibility of the linker design to allow insertion of immunostimulatory genes in future constructs, makes this a useful base vector for immunization against primate lentiviruses. We present the construction of a retroviral plasmid designed to serve as a template for the development of safe and effective vaccines against primate immunodeficiency retroviruses. This vaccine component should facilitate the simultaneous induction of cellular and humoral immune responses that protect primates against infection with SIV and human immunodeficiency virus (HIV) and the development of acquired immune deficiency syndrome (AIDS). This plasmid could induce the appropriate immune response required to attack both cell-free and cell-associated viruses. The lack of infectivity, the inability to integrate, and the SIV origin make this construct a safe alternative to attenuated vaccines based on HIV. In addition, we intend to develop this construct as an immunotherapeutic approach to lower the viremia in AIDS patients.

Original languageEnglish (US)
Pages (from-to)339-348
Number of pages10
JournalViral Immunology
Volume14
Issue number4
StatePublished - 2001

Fingerprint

Simian Immunodeficiency Virus
DNA Vaccines
Humoral Immunity
Cellular Immunity
Primates
Acquired Immunodeficiency Syndrome
Plasmids
Vaccines
Primate Lentiviruses
vif Genes
HIV
vpr Genes
Satellite Viruses
Integrases
Attenuated Vaccines
Terminal Repeat Sequences
Insertional Mutagenesis
Viremia
Retroviridae
Cytomegalovirus

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

A retroviral DNA vaccine vector. / Smith, James M.; Torres, Jose V.

In: Viral Immunology, Vol. 14, No. 4, 2001, p. 339-348.

Research output: Contribution to journalArticle

Smith, JM & Torres, JV 2001, 'A retroviral DNA vaccine vector', Viral Immunology, vol. 14, no. 4, pp. 339-348.
Smith, James M. ; Torres, Jose V. / A retroviral DNA vaccine vector. In: Viral Immunology. 2001 ; Vol. 14, No. 4. pp. 339-348.
@article{0043364ad4314d2ca7d01dd7419b8e94,
title = "A retroviral DNA vaccine vector",
abstract = "A versatile DNA vaccine (pdIV3) was constructed by replacing the integrase, vif, vpx, and vpr genes of a pathogenic simian immunodeficiency virus (SIV) molecular clone with a linker containing unique cloning sites. The 5′ long terminal repeat (LTR) is truncated and transcription is controlled by a cytomegalovirus (CMV) promoter. The construct expresses Gag and Env in vitro and noninfectious virus particles are produced from transfected cells. The ability of pdIV3 to promote cellular and humoral immune responses, along with the flexibility of the linker design to allow insertion of immunostimulatory genes in future constructs, makes this a useful base vector for immunization against primate lentiviruses. We present the construction of a retroviral plasmid designed to serve as a template for the development of safe and effective vaccines against primate immunodeficiency retroviruses. This vaccine component should facilitate the simultaneous induction of cellular and humoral immune responses that protect primates against infection with SIV and human immunodeficiency virus (HIV) and the development of acquired immune deficiency syndrome (AIDS). This plasmid could induce the appropriate immune response required to attack both cell-free and cell-associated viruses. The lack of infectivity, the inability to integrate, and the SIV origin make this construct a safe alternative to attenuated vaccines based on HIV. In addition, we intend to develop this construct as an immunotherapeutic approach to lower the viremia in AIDS patients.",
author = "Smith, {James M.} and Torres, {Jose V}",
year = "2001",
language = "English (US)",
volume = "14",
pages = "339--348",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - A retroviral DNA vaccine vector

AU - Smith, James M.

AU - Torres, Jose V

PY - 2001

Y1 - 2001

N2 - A versatile DNA vaccine (pdIV3) was constructed by replacing the integrase, vif, vpx, and vpr genes of a pathogenic simian immunodeficiency virus (SIV) molecular clone with a linker containing unique cloning sites. The 5′ long terminal repeat (LTR) is truncated and transcription is controlled by a cytomegalovirus (CMV) promoter. The construct expresses Gag and Env in vitro and noninfectious virus particles are produced from transfected cells. The ability of pdIV3 to promote cellular and humoral immune responses, along with the flexibility of the linker design to allow insertion of immunostimulatory genes in future constructs, makes this a useful base vector for immunization against primate lentiviruses. We present the construction of a retroviral plasmid designed to serve as a template for the development of safe and effective vaccines against primate immunodeficiency retroviruses. This vaccine component should facilitate the simultaneous induction of cellular and humoral immune responses that protect primates against infection with SIV and human immunodeficiency virus (HIV) and the development of acquired immune deficiency syndrome (AIDS). This plasmid could induce the appropriate immune response required to attack both cell-free and cell-associated viruses. The lack of infectivity, the inability to integrate, and the SIV origin make this construct a safe alternative to attenuated vaccines based on HIV. In addition, we intend to develop this construct as an immunotherapeutic approach to lower the viremia in AIDS patients.

AB - A versatile DNA vaccine (pdIV3) was constructed by replacing the integrase, vif, vpx, and vpr genes of a pathogenic simian immunodeficiency virus (SIV) molecular clone with a linker containing unique cloning sites. The 5′ long terminal repeat (LTR) is truncated and transcription is controlled by a cytomegalovirus (CMV) promoter. The construct expresses Gag and Env in vitro and noninfectious virus particles are produced from transfected cells. The ability of pdIV3 to promote cellular and humoral immune responses, along with the flexibility of the linker design to allow insertion of immunostimulatory genes in future constructs, makes this a useful base vector for immunization against primate lentiviruses. We present the construction of a retroviral plasmid designed to serve as a template for the development of safe and effective vaccines against primate immunodeficiency retroviruses. This vaccine component should facilitate the simultaneous induction of cellular and humoral immune responses that protect primates against infection with SIV and human immunodeficiency virus (HIV) and the development of acquired immune deficiency syndrome (AIDS). This plasmid could induce the appropriate immune response required to attack both cell-free and cell-associated viruses. The lack of infectivity, the inability to integrate, and the SIV origin make this construct a safe alternative to attenuated vaccines based on HIV. In addition, we intend to develop this construct as an immunotherapeutic approach to lower the viremia in AIDS patients.

UR - http://www.scopus.com/inward/record.url?scp=0035734564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035734564&partnerID=8YFLogxK

M3 - Article

C2 - 11792063

AN - SCOPUS:0035734564

VL - 14

SP - 339

EP - 348

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 4

ER -